A Phase 2 interventional study of Placebo (Cohorts 1 and 2) and PF-06882961 (Cohorts 1 and 2) in Obesity, sponsored by Pfizer. Completed at 41 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-05.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Obesity by Pfizer — 13 open to participants now, 19 under way, 12 of them phase 3. Obesity · Pfizer.
Among the 64 studies in Obesity by Pfizer, this one is the 14th largest by enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2021, is one of 11 in phase 2, and was the 29th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →13 of the 64 studies in Obesity by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 14 · Phase 3 17
First in 2004; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 628 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 127 across the 62 interventional studies, 53,752 across the 2 observational. Of the 43 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
8 of the studies in Obesity by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311850Phase 3PfizerEfficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | 2027-09-21 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07725809PfizerA Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity | 2027-01-13 |
| NCT07508241PfizerA Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity | 2027-01-27 |
| NCT07845513PfizerA Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity | 2027-02-21 |
Add all 8 to your calendar (.ics) → With an account.
Among the 64 studies in Obesity by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-06882961) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-06882961) to those of participants who take placebo (a look- alike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight, waist and hip measurements, how well they tolerate the study medicine, and to measure levels of the study medicine in participants' blood.
This study is seeking participants who have obesity, who do not have diabetes and who have had a stable body weight and not participated in a formal weight loss program in the 90 days before the study. The study medicine or placebo will be taken as tablets by mouth 2 times a day (1 time in the morning and 1 time in the evening).
There are 3 groups of participants (called cohorts) in this study. For participants in Cohorts 1 and 2, total study participation will be about 9 months, with 15 planned study visits (14 visits to the study clinic and 1 telephone call). For participants in Cohort 3, total study participation will be about 10 months, with 21 planned study visits (12 visits to the study clinic and 9 telephone calls).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo (Cohorts 1 and 2)
The dose will be titrated with 1 week of dosing at each step to reach the target dose of 40 mg BID.
Drug: PF-06882961 (Cohorts 1 and 2)
The dose will be titrated with 1 week of dosing at each step to reach the target dose of 80 mg BID.
Drug: PF-06882961 (Cohorts 1 and 2)
The dose will be titrated with 1 week of dosing at each step to reach the target dose of 120 mg BID.
Drug: PF-06882961 (Cohorts 1 and 2)
The dose will be titrated with 1 week of dosing at each step to reach the target dose of 160 mg BID.
Drug: PF-06882961 (Cohorts 1 and 2)
The dose will be titrated with 1 week of dosing at each step to reach the target dose of 200 mg BID.
Drug: PF-06882961 (Cohorts 1 and 2)
The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 120 mg BID.
Drug: PF-06882961 (Cohorts 1 and 2)
The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 160 mg BID.
Drug: PF-06882961 (Cohorts 1 and 2)
The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 200 mg BID.
Drug: PF-06882961 (Cohorts 1 and 2)
Drug: Placebo (Cohort 3)
The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 80 mg BID.
Drug: PF-06882961 (Cohort 3)
The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 140 mg BID.
Drug: PF-06882961 (Cohort 3)
The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 200 mg BID.
Drug: PF-06882961 (Cohort 3)
4 matching placebo tablets taken twice daily
Drug page: Danuglipron
Participants will be randomized to one of 5 active target dose levels (40, 80, 120, 160 or 200 mg BID) achieved through 1-week titration steps, or 3 active target dose levels (120, 160 or 200 mg BID) achieved through 2-week titration steps, taking 4 tablets twice daily
2 matching placebo tablets taken twice daily
Participants will be randomized to one of 3 active target dose levels (80, 140 or 200 mg BID) achieved through 4-week titration steps, taking 2 tablets twice daily.
Cohorts 1 and 2: Percent Change From Baseline in Body Weight at End of Treatment at Week 26
Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100 multiply by \[\*\](back-transformed LS Mean minus \[-\] 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
Time frame: Baseline, Week 26
Cohort 3: Percent Change From Baseline in Body Weight at End of Treatment at Week 32
Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100\*(back-transformed LS Mean - 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
Time frame: Baseline, Week 32
Cohorts 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (TESAEs)
An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose met one or more of the criteria such as resulted in death; life threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent disability or incapacity, congenital anomaly or birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. An adverse event is considered treatment-emergent relative to given treatment if the event starts during the effective duration of the treatment (i.e. starting on or after the first dose but before the last dose plus follow-up period).
Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (maximum up to 31 weeks)
Cohort 3: Number of Participants With TEAEs and TESAEs
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose met one or more of the criteria such as resulted in death; life threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent disability or incapacity, congenital anomaly or birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. An adverse event is considered treatment-emergent relative to given treatment if the event starts during the effective duration of the treatment (i.e. starting on or after the first dose but before the last dose plus lag time).
Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (maximum up to 37 weeks)
Cohorts 1 and 2: Number of Participants With Laboratory Abnormalities, Without Regard to Baseline Abnormality
Laboratory parameters:a)hematology:hemoglobin(Hg),hematocrit,erythrocytes(ery),neutrophils,ery mean corpuscular volume,platelets,leukocytes(leu),lymphocytes,basophils,eosinophils,monocytes activated partial thromboplastin time, prothrombin time,prothrombin initial normalised ratio b)chemistry:direct bilirubin(bil),indirect bil, gamma glutamyl transferase,urea nitrogen,urate,sodium,potassium,calcium(cal),cal corrected,bicarbonate,Hg a1c,creatine kinase,bile acid,calcitonin,insulin-fasting,glucose fasting,amylase,lipase,thyrotropin,thyroxine,free,cholesterol,high density lipoprotein (hdl) cholesterol,triglycerides,alanine aminotransferase c)urinalysis:urine:pH,ketone,protein, Hg, urobilinogen,nitrite,leu esterase,ery,leu,tubular epithelial cells,squamous epithelial cells,granular casts,hyaline casts,uric acid crystals,calcium oxalate crystals,amorphous crystals,mucus,microscopic exam,spermatozoa,yeast budding,transitional epithelial cells,leu cell clumps;yeast hyphae.
Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 31 weeks)
Cohort 3: Number of Participants With Laboratory Abnormalities, Without Regard to Baseline Abnormality
Laboratory parameters:a)hematology:hemoglobin(Hg),hematocrit,erythrocytes(ery),neutrophils,ery mean corpuscular volume,platelets,leukocytes(leu),lymphocytes,basophils,eosinophils,monocytes activated partial thromboplastin time, prothrombin time,prothrombin initial normalised ratio b)chemistry:direct bilirubin(bil),indirect bil, gamma glutamyl transferase,urea nitrogen,urate,sodium,potassium,calcium(cal),cal corrected,bicarbonate,Hg a1c,creatine kinase,bile acid,calcitonin,insulin-fasting,glucose fasting,amylase,lipase,thyrotropin,thyroxine,free,cholesterol,high density lipoprotein (hdl) cholesterol,triglycerides,alanine aminotransferase c)urinalysis:urine:pH,ketone,protein, Hg, urobilinogen,nitrite,leu esterase,ery,leu,tubular epithelial cells,squamous epithelial cells,granular casts,hyaline casts,uric acid crystals,calcium oxalate crystals,amorphous crystals,mucus,microscopic exam,spermatozoa,yeast budding,transitional epithelial cells,leu cell clumps;yeast hyphae.
Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 37 weeks)
Cohorts 1 and 2: Number of Participants According to Categorization of Vital Signs Data
Vital signs of systolic blood pressure, diastolic blood pressure and pulse rate and were measured using an automated device with the participant in a supine position after five minutes of rest. This reports the number of participants that met the following pre-specified criteria: systolic blood pressure (SBP) \<90 millimetres of mercury (mmHg), diastolic blood pressure (DBP) \<50 mmHg, pulse rate (PR) \<40 beats per minute, \>120 beats per minute.
Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 31 weeks)
Cohort 3: Number of Participants According to Categorization of Vital Signs Data
Vital signs of systolic blood pressure, diastolic blood pressure and pulse rate and were measured using an automated device with the participant in a supine position after five minutes of rest. This reports the number of participants that met the following pre-specified criteria: systolic blood pressure (SBP) \<90 millimetres of mercury (mmHg), diastolic blood pressure (DBP) \<50 mmHg, pulse rate (PR) \<40 beats per minute, \>120 beats per minute.
Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 37 weeks)
Cohorts 1 and 2: Number of Participants According to Categorization of Electrocardiogram (ECG) Parameters
Standard 12-lead ECGs were measured with the participant in a supine position after at least five minutes of rest. This reports the number of participants that met the following pre-specified criteria for ECG: QRS interval \>=140; PR interval \>=300; QTCF interval \>500.
Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 31 weeks)
Cohort 3: Number of Participants According to Categorization of ECG Parameters
Standard 12-lead ECGs were measured with the participant in a supine position after at least five minutes of rest. This reports the number of participants that met the following pre-specified criteria for ECG: QRS interval \>=140; PR interval \>=300; QTCF interval \>500.
Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 37 weeks)
Cohorts 1 and 2: Number of Participants With Categorical Scores on Columbia-Suicide Severity Rating Scale (C-SSRS) Leading to Study Discontinuation
C-SSRS is an interview-based rating scale to assess suicidal ideation and behavior. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.
Time frame: Week 0 (Baseline), 2, 4, 6, 8, 10, 12, 16, 18, 22, 26, Follow-up (Week 31)
Cohort 3: Number of Participants With Categorical Scores on C-SSRS Leading to Study Discontinuation
C-SSRS is an interview-based rating scale to assess suicidal ideation and behavior. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.
Time frame: Week 0 (Baseline), 4, 8, 12, 16, 20, 24, 28, 32, Follow-up (Week 37)
Cohort 1 and 2: Number of Participants With Scores on the Patient Health Questionnaire-9 (PHQ-9) Leading to Study Discontinuation
PHQ-9 is a self-reported, nine-item scale for the assessment of depressive disorder. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.
Time frame: Week 0 (Baseline) , 2, 4, 6, 8, 10, 12, 16, 18, 22, 26, Follow-up (Week 31)
Cohort 3: Number of Participants With Scores on the PHQ-9 Leading to Study Discontinuation
PHQ-9 is a self-reported, nine-item scale for the assessment of depressive disorder. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.
Time frame: Week 0 (Baseline), 4, 8, 12, 16, 20, 24, 28, 32, Follow-up (Week 37)
Cohorts 1 and 2: Number of Participants With >= 5% Body Weight Loss at End of Treatment
Number of participants with \>= 5% body weight loss at end of treatment were reported.
Time frame: Week 26
Cohort 3: Number of Participants With >=5% Body Weight Loss at End of Treatment
Number of participants with \>= 5% body weight loss at end of treatment were reported.
Time frame: Week 32
Cohorts 1 and 2: Percent Change From Baseline in Body Weight at Weeks 2, 4, 6, 8, 10, 12,16, 18, 22
Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100\*(back-transformed LS Mean - 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12,16, 18, 22
Cohort 3: Percent Change From Baseline in Body Weight at Weeks 4, 8, 12, 16, 20, 24 and 28
Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100\*(back-transformed LS Mean - 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24 and 28
Cohorts 1 and 2: Absolute Change From Baseline in Waist Circumference at End of Treatment at Week 26
Absolute change from baseline in waist circumference were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
Time frame: Baseline, Week 26
Cohort 3: Absolute Change From Baseline in Waist Circumference at End of Treatment at Week 32
Absolute change from baseline in waist circumference were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
Time frame: Baseline, Week 32
Cohorts 1 and 2: Absolute Change From Baseline in Waist-to-hip Ratio at End of Treatment at Week 26
Absolute change from baseline in waist-to-hip ratio at end of treatment were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
Time frame: Baseline, Week 26
Cohort 3: Absolute Change From Baseline in Waist-to-hip Ratio at End of Treatment at Week 32
Absolute change from baseline in waist-to-hip ratio at end of treatment were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
Time frame: Baseline, Week 32
Cohorts 1 and 2: Absolute Change From Baseline in Percentage Hemoglobin A1c (HbA1c) at Weeks 16 and 26
Absolute change from baseline in HbA1c were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
Time frame: Baseline, Weeks 16 and 26
Cohort 3: Absolute Change From Baseline in Percentage HbA1c at Weeks 16, 24 and 32
Absolute change from baseline in HbA1c were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
Time frame: Baseline, Weeks 16, 24 and 32
Cohorts 1 and 2: Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 2, 4, 6, 8, 10, 12, 16, 18, 22, 26
Absolute change from baseline in FPG were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 16, 18, 22, 26
Cohort 3: Absolute Change From Baseline in FPG at Weeks 4, 8, 12, 16, 20, 24, 28, 32
Absolute change from baseline in FPG were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
| Milestone | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40 mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 71 | 62 | 64 | 64 | 38 | 63 | 37 | 64 | 36 | 0 | 0 | 0 | 0 |
| Received treatment | 71 | 62 | 63 | 64 | 38 | 63 | 37 | 63 | 36 | 0 | 0 | 0 | 0 |
| Completed | 44 | 27 | 30 | 26 | 13 | 18 | 11 | 14 | 13 | 0 | 0 | 0 | 0 |
| Not completed | 27 | 35 | 34 | 38 | 25 | 45 | 26 | 50 | 23 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 20 | 23 | 25 | 15 | 38 | 15 | 42 | 16 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 5 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 4 | 4 | 5 | 3 | 2 | 3 | 2 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 4 | 1 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 11 | 5 | 3 | 7 | 3 | 4 | 6 | 4 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized not treated | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40 mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 37 | 37 | 36 |
| Received treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 37 | 37 | 36 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 13 | 15 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 24 | 22 | 25 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 16 | 18 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 2 | 3 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 3 | 3 |
Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100 multiply by \[\*\](back-transformed LS Mean minus \[-\] 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
| Percent change | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) |
|---|---|---|---|---|---|---|---|---|---|
| Cohorts 1 and 2: Percent Change From Baseline in Body Weight at End of Treatment at Week 26 | 0.17 ± 0.008 | -5.43 ± 0.009 | -4.83 ± 0.009 | -8.94 ± 0.009 | -6.43 ± 0.012 | -9.36 ± 0.010 | -6.96 ± 0.013 | -8.96 ± 0.011 | -7.02 ± 0.012 |
Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100\*(back-transformed LS Mean - 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
| Percent change | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|
| Cohort 3: Percent Change From Baseline in Body Weight at End of Treatment at Week 32 | 1.40 ± 0.018 | -6.92 ± 0.014 | -7.15 ± 0.014 | -11.65 ± 0.014 |
An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose met one or more of the criteria such as resulted in death; life threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent disability or incapacity, congenital anomaly or birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. An adverse event is considered treatment-emergent relative to given treatment if the event starts during the effective duration of the treatment (i.e. starting on or after the first dose but before the last dose plus follow-up period).
| Participants | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) |
|---|---|---|---|---|---|---|---|---|---|
| TEAEs | 50 | 52 | 59 | 54 | 32 | 59 | 30 | 59 | 30 |
| TESAEs | 1 | 2 | 1 | 0 | 1 | 1 | 0 | 5 | 1 |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose met one or more of the criteria such as resulted in death; life threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent disability or incapacity, congenital anomaly or birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. An adverse event is considered treatment-emergent relative to given treatment if the event starts during the effective duration of the treatment (i.e. starting on or after the first dose but before the last dose plus lag time).
| Participants | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|
| TEAEs | 13 | 30 | 34 | 34 |
| TESAEs | 0 | 2 | 2 | 3 |
Laboratory parameters:a)hematology:hemoglobin(Hg),hematocrit,erythrocytes(ery),neutrophils,ery mean corpuscular volume,platelets,leukocytes(leu),lymphocytes,basophils,eosinophils,monocytes activated partial thromboplastin time, prothrombin time,prothrombin initial normalised ratio b)chemistry:direct bilirubin(bil),indirect bil, gamma glutamyl transferase,urea nitrogen,urate,sodium,potassium,calcium(cal),cal corrected,bicarbonate,Hg a1c,creatine kinase,bile acid,calcitonin,insulin-fasting,glucose fasting,amylase,lipase,thyrotropin,thyroxine,free,cholesterol,high density lipoprotein (hdl) cholesterol,triglycerides,alanine aminotransferase c)urinalysis:urine:pH,ketone,protein, Hg, urobilinogen,nitrite,leu esterase,ery,leu,tubular epithelial cells,squamous epithelial cells,granular casts,hyaline casts,uric acid crystals,calcium oxalate crystals,amorphous crystals,mucus,microscopic exam,spermatozoa,yeast budding,transitional epithelial cells,leu cell clumps;yeast hyphae.
| Participants | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) |
|---|---|---|---|---|---|---|---|---|---|
| Cohorts 1 and 2: Number of Participants With Laboratory Abnormalities, Without Regard to Baseline Abnormality | 66 | 56 | 60 | 57 | 37 | 54 | 33 | 59 | 33 |
Laboratory parameters:a)hematology:hemoglobin(Hg),hematocrit,erythrocytes(ery),neutrophils,ery mean corpuscular volume,platelets,leukocytes(leu),lymphocytes,basophils,eosinophils,monocytes activated partial thromboplastin time, prothrombin time,prothrombin initial normalised ratio b)chemistry:direct bilirubin(bil),indirect bil, gamma glutamyl transferase,urea nitrogen,urate,sodium,potassium,calcium(cal),cal corrected,bicarbonate,Hg a1c,creatine kinase,bile acid,calcitonin,insulin-fasting,glucose fasting,amylase,lipase,thyrotropin,thyroxine,free,cholesterol,high density lipoprotein (hdl) cholesterol,triglycerides,alanine aminotransferase c)urinalysis:urine:pH,ketone,protein, Hg, urobilinogen,nitrite,leu esterase,ery,leu,tubular epithelial cells,squamous epithelial cells,granular casts,hyaline casts,uric acid crystals,calcium oxalate crystals,amorphous crystals,mucus,microscopic exam,spermatozoa,yeast budding,transitional epithelial cells,leu cell clumps;yeast hyphae.
| Participants | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|
| Cohort 3: Number of Participants With Laboratory Abnormalities, Without Regard to Baseline Abnormality | 15 | 31 | 34 | 32 |
Vital signs of systolic blood pressure, diastolic blood pressure and pulse rate and were measured using an automated device with the participant in a supine position after five minutes of rest. This reports the number of participants that met the following pre-specified criteria: systolic blood pressure (SBP) \<90 millimetres of mercury (mmHg), diastolic blood pressure (DBP) \<50 mmHg, pulse rate (PR) \<40 beats per minute, \>120 beats per minute.
| Participants | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) |
|---|---|---|---|---|---|---|---|---|---|
| SBP Value < 90 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 0 | 0 |
| DBP Value < 50 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR <40 beats per minute | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR >120 beats per minute | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Vital signs of systolic blood pressure, diastolic blood pressure and pulse rate and were measured using an automated device with the participant in a supine position after five minutes of rest. This reports the number of participants that met the following pre-specified criteria: systolic blood pressure (SBP) \<90 millimetres of mercury (mmHg), diastolic blood pressure (DBP) \<50 mmHg, pulse rate (PR) \<40 beats per minute, \>120 beats per minute.
| Participants | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|
| DBP Value < 50 | 0 | 0 | 1 | 0 |
| SBP Value < 90 | 0 | 0 | 0 | 0 |
| PR <40 beats per minute | 0 | 0 | 0 | 0 |
| PR >120 beats per minute | 0 | 0 | 0 | 0 |
Standard 12-lead ECGs were measured with the participant in a supine position after at least five minutes of rest. This reports the number of participants that met the following pre-specified criteria for ECG: QRS interval \>=140; PR interval \>=300; QTCF interval \>500.
| Participants | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) |
|---|---|---|---|---|---|---|---|---|---|
| QRS interval >=140 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| QTCF interval >500 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR interval >=300 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Standard 12-lead ECGs were measured with the participant in a supine position after at least five minutes of rest. This reports the number of participants that met the following pre-specified criteria for ECG: QRS interval \>=140; PR interval \>=300; QTCF interval \>500.
| Participants | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|
| QRS interval >=140 | 0 | 0 | 0 | 1 |
| QTCF interval >500 | 0 | 0 | 0 | 0 |
| PR interval >=300 | 0 | 0 | 0 | 0 |
C-SSRS is an interview-based rating scale to assess suicidal ideation and behavior. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.
| Participants | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) |
|---|---|---|---|---|---|---|---|---|---|
| Cohorts 1 and 2: Number of Participants With Categorical Scores on Columbia-Suicide Severity Rating Scale (C-SSRS) Leading to Study Discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
C-SSRS is an interview-based rating scale to assess suicidal ideation and behavior. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.
| Participants | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|
| Cohort 3: Number of Participants With Categorical Scores on C-SSRS Leading to Study Discontinuation | 0 | 0 | 0 | 0 |
PHQ-9 is a self-reported, nine-item scale for the assessment of depressive disorder. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.
| Participants | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) |
|---|---|---|---|---|---|---|---|---|---|
| Cohort 1 and 2: Number of Participants With Scores on the Patient Health Questionnaire-9 (PHQ-9) Leading to Study Discontinuation | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
PHQ-9 is a self-reported, nine-item scale for the assessment of depressive disorder. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.
| Participants | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|
| Cohort 3: Number of Participants With Scores on the PHQ-9 Leading to Study Discontinuation | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
Number of participants with \>= 5% body weight loss at end of treatment were reported.
| Participants | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) |
|---|---|---|---|---|---|---|---|---|---|
| Cohorts 1 and 2: Number of Participants With >= 5% Body Weight Loss at End of Treatment | 6 | 16 | 15 | 17 | 12 | 15 | 6 | 12 | 8 |
Number of participants with \>= 5% body weight loss at end of treatment were reported.
| Participants | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|
| Cohort 3: Number of Participants With >=5% Body Weight Loss at End of Treatment | 0 | 9 | 11 | 10 |
Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100\*(back-transformed LS Mean - 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
| Percent Change | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) |
|---|---|---|---|---|---|---|---|---|---|
| Week 2 | -0.13 ± 0.001 | -0.85 ± 0.001 | -0.54 ± 0.001 | -0.98 ± 0.001 | -0.58 ± 0.002 | -0.87 ± 0.001 | -0.22 ± 0.002 | -0.96 ± 0.001 | -0.53 ± 0.002 |
| Week 4 | -0.15 ± 0.002 | -1.65 ± 0.002 | -1.69 ± 0.002 | -1.99 ± 0.002 | -1.26 ± 0.003 | -1.71 ± 0.002 | -0.93 ± 0.003 | -1.98 ± 0.002 | -1.28 ± 0.003 |
| Week 6 | -0.24 ± 0.003 | -2.26 ± 0.003 | -2.37 ± 0.003 | -2.96 ± 0.003 | -1.99 ± 0.003 | -2.84 ± 0.003 | -1.93 ± 0.004 | -2.97 ± 0.003 | -1.99 ± 0.004 |
| Week 8 | -0.41 ± 0.003 | -2.93 ± 0.003 | -2.86 ± 0.003 | -3.89 ± 0.003 | -3.33 ± 0.004 | -3.87 ± 0.004 | -2.34 ± 0.004 | -3.83 ± 0.004 | -2.94 ± 0.004 |
| Week 10 | -0.50 ± 0.004 | -3.47 ± 0.004 | -3.33 ± 0.004 | -4.82 ± 0.004 | -3.92 ± 0.005 | -4.67 ± 0.004 | -3.20 ± 0.005 | -4.54 ± 0.004 | -3.83 ± 0.005 |
| Week 12 | -0.44 ± 0.004 | -3.89 ± 0.005 | -3.88 ± 0.004 | -5.31 ± 0.005 | -4.49 ± 0.006 | -5.66 ± 0.005 | -3.98 ± 0.006 | -5.33 ± 0.005 | -4.34 ± 0.006 |
| Week 16 | -0.40 ± 0.005 | -4.73 ± 0.006 | -4.01 ± 0.006 | -6.98 ± 0.006 | -5.49 ± 0.008 | -7.04 ± 0.007 | -5.15 ± 0.008 | -6.56 ± 0.007 | -5.18 ± 0.008 |
| Week 18 | -0.50 ± 0.006 | -4.94 ± 0.006 | -4.68 ± 0.006 | -7.33 ± 0.007 | -6.33 ± 0.008 | -7.50 ± 0.007 | -5.57 ± 0.009 | -7.27 ± 0.007 | -5.80 ± 0.008 |
| Week 22 | -0.18 ± 0.007 | -5.06 ± 0.008 | -5.00 ± 0.007 | -8.10 ± 0.008 | -6.43 ± 0.010 | -8.63 ± 0.009 | -6.57 ± 0.011 | -8.23 ± 0.009 | -6.60 ± 0.010 |
Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100\*(back-transformed LS Mean - 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
| Percent Change | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|
| Week 4 | -0.37 ± 0.004 | -1.38 ± 0.003 | -0.95 ± 0.003 | -1.02 ± 0.003 |
| Week 8 | -0.06 ± 0.006 | -2.07 ± 0.004 | -1.93 ± 0.004 | -1.89 ± 0.004 |
| Week 12 | -0.08 ± 0.008 | -2.80 ± 0.006 | -2.88 ± 0.005 | -2.96 ± 0.006 |
| Week 16 | 0.03 ± 0.011 | -4.13 ± 0.008 | -3.99 ± 0.007 | -4.73 ± 0.008 |
| Week 20 | 0.38 ± 0.014 | -5.17 ± 0.010 | -5.25 ± 0.009 | -7.10 ± 0.010 |
| Week 24 | 0.36 ± 0.015 | -5.65 ± 0.011 | -6.39 ± 0.011 | -9.20 ± 0.011 |
| Week 28 | 1.06 ± 0.017 | -6.37 ± 0.013 | -6.74 ± 0.012 | -10.44 ± 0.013 |
Absolute change from baseline in waist circumference were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
| Centimeter | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) |
|---|---|---|---|---|---|---|---|---|---|
| Cohorts 1 and 2: Absolute Change From Baseline in Waist Circumference at End of Treatment at Week 26 | -1.25 ± 0.826 | -6.49 ± 0.995 | -5.75 ± 0.943 | -6.19 ± 1.023 | -5.98 ± 1.338 | -9.05 ± 1.174 | -7.41 ± 1.490 | -7.56 ± 1.281 | -6.36 ± 1.350 |
Absolute change from baseline in waist circumference were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
| Centimeter | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|
| Cohort 3: Absolute Change From Baseline in Waist Circumference at End of Treatment at Week 32 | 0.19 ± 1.967 | -6.27 ± 1.628 | -7.77 ± 1.564 | -11.43 ± 1.698 |
Absolute change from baseline in waist-to-hip ratio at end of treatment were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
| Ratio | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) |
|---|---|---|---|---|---|---|---|---|---|
| Cohorts 1 and 2: Absolute Change From Baseline in Waist-to-hip Ratio at End of Treatment at Week 26 | -0.002 ± 0.0064 | -0.002 ± 0.0076 | -0.015 ± 0.0073 | 0.001 ± 0.0078 | -0.014 ± 0.0104 | -0.015 ± 0.0090 | -0.014 ± 0.0114 | -0.007 ± 0.0098 | 0.004 ± 0.0104 |
Absolute change from baseline in waist-to-hip ratio at end of treatment were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
| Ratio | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|
| Cohort 3: Absolute Change From Baseline in Waist-to-hip Ratio at End of Treatment at Week 32 | 0.010 ± 0.0128 | -0.012 ± 0.0113 | -0.009 ± 0.0108 | -0.016 ± 0.0121 |
Absolute change from baseline in HbA1c were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
| Percentage of HbA1c | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) |
|---|---|---|---|---|---|---|---|---|---|
| Week 16 | 0.00 ± 0.034 | -0.24 ± 0.039 | -0.24 ± 0.039 | -0.26 ± 0.042 | -0.25 ± 0.056 | -0.29 ± 0.050 | -0.18 ± 0.061 | -0.23 ± 0.053 | -0.24 ± 0.054 |
| Week 26 | 0.01 ± 0.036 | -0.17 ± 0.045 | -0.13 ± 0.044 | -0.22 ± 0.046 | -0.16 ± 0.064 | -0.31 ± 0.055 | -0.13 ± 0.070 | -0.17 ± 0.062 | -0.26 ± 0.064 |
Absolute change from baseline in HbA1c were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
| Percentage of HbA1c | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|
| Week 16 | -0.05 ± 0.061 | -0.16 ± 0.048 | -0.26 ± 0.044 | -0.29 ± 0.042 |
| Week 24 | 0.05 ± 0.070 | -0.13 ± 0.059 | -0.21 ± 0.055 | -0.31 ± 0.059 |
| Week 32 | -0.02 ± 0.074 | -0.11 ± 0.064 | -0.27 ± 0.059 | -0.41 ± 0.068 |
Absolute change from baseline in FPG were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
| Milligram per deciliter | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) |
|---|---|---|---|---|---|---|---|---|---|
| Week 2 | 3.22 ± 0.903 | -2.93 ± 0.963 | -2.56 ± 0.939 | -4.02 ± 0.940 | -2.02 ± 1.245 | -4.51 ± 0.957 | -1.16 ± 1.265 | -2.82 ± 0.939 | -2.93 ± 1.250 |
| Week 4 | 3.38 ± 1.082 | -2.75 ± 1.196 | -2.97 ± 1.166 | -3.59 ± 1.155 | -0.83 ± 1.443 | -4.81 ± 1.199 | -2.56 ± 1.504 | -6.24 ± 1.164 | -3.86 ± 1.485 |
| Week 6 | 1.45 ± 0.936 | -4.28 ± 1.021 | -2.29 ± 1.035 | -6.38 ± 1.044 | -4.17 ± 1.290 | -3.46 ± 1.102 | -3.06 ± 1.371 | -4.32 ± 1.095 | -4.64 ± 1.311 |
| Week 8 | 1.61 ± 0.956 | -3.72 ± 1.068 | -3.15 ± 1.103 | -2.56 ± 1.130 | -2.77 ± 1.385 | -4.48 ± 1.177 | -4.07 ± 1.438 | -4.90 ± 1.248 | -2.82 ± 1.367 |
| Week 10 | 2.47 ± 1.146 | -2.52 ± 1.264 | -1.79 ± 1.251 | -4.74 ± 1.353 | -2.60 ± 1.662 | -4.17 ± 1.498 | -5.26 ± 1.702 | -5.35 ± 1.525 | -2.85 ± 1.558 |
| Week 12 | 2.57 ± 1.229 | -2.70 ± 1.408 | -0.77 ± 1.377 | -2.24 ± 1.492 | -1.22 ± 1.889 | -4.86 ± 1.686 | -4.65 ± 1.908 | -3.01 ± 1.716 | -3.19 ± 1.764 |
| Week 16 | 0.50 ± 1.352 | -2.67 ± 1.523 | -2.04 ± 1.537 | -2.56 ± 1.619 | -6.99 ± 2.143 | -6.62 ± 1.926 | -5.73 ± 2.338 | -4.67 ± 2.011 | -5.24 ± 2.097 |
| Week 18 | 4.34 ± 1.407 | -0.44 ± 1.634 | -3.73 ± 1.593 | 0.19 ± 1.770 | -0.96 ± 2.294 | -4.76 ± 2.030 | -5.23 ± 2.684 | 0.11 ± 2.175 | 0.53 ± 2.189 |
| Week 22 | 4.83 ± 1.494 | 0.38 ± 1.872 | -3.22 ± 1.712 | -4.27 ± 1.842 | -1.78 ± 2.502 | -2.03 ± 2.205 | -1.65 ± 2.888 | -4.64 ± 2.460 | -5.08 ± 2.580 |
| Week 26 | 3.34 ± 1.220 | -3.37 ± 1.499 | -3.43 ± 1.469 | -4.02 ± 1.555 | -3.75 ± 2.059 | -6.00 ± 1.804 | -3.50 ± 2.290 | -6.60 ± 2.010 | -5.01 ± 2.172 |
Absolute change from baseline in FPG were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.
| Milligram per deciliter | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|
| Week 4 | -1.82 ± 2.327 | -0.83 ± 1.652 | 0.96 ± 1.616 | 3.84 ± 1.671 |
| Week 8 | 0.10 ± 2.523 | 1.79 ± 1.748 | -1.16 ± 1.659 | 2.52 ± 1.720 |
| Week 12 | -1.28 ± 2.588 | -1.80 ± 1.883 | 1.56 ± 1.755 | -0.42 ± 1.761 |
| Week 16 | -5.75 ± 2.348 | -5.18 ± 1.778 | -2.43 ± 1.654 | 0.88 ± 1.618 |
| Week 20 | 1.52 ± 2.175 | -1.95 ± 1.774 | -4.78 ± 1.687 | -1.39 ± 1.628 |
| Week 24 | -2.80 ± 2.664 | -0.13 ± 2.088 | -2.00 ± 2.014 | 1.62 ± 2.158 |
| Week 28 | 1.67 ± 2.518 | -0.15 ± 2.044 | -4.53 ± 1.983 | 0.90 ± 2.221 |
| Week 32 | -1.81 ± 3.006 | 1.28 ± 2.491 | -1.65 ± 2.446 | -1.73 ± 2.582 |
Collected over From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (maximum up to Week 31 for Cohort 1 and 2; maximum up to Week 37 for Cohort 3). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohorts 1 and 2: Placebo | 0/71 (0%) | 1/71 (1.4%) | 29/71 (40.8%) |
| Cohort 1: PF-06882961 40 mg BID (1-week Titration) | 0/62 (0%) | 2/62 (3.2%) | 46/62 (74.2%) |
| Cohort 1: PF-06882961 80mg BID (1-week Titration) | 0/63 (0%) | 1/63 (1.6%) | 53/63 (84.1%) |
| Cohort 1: PF-06882961 120mg BID (1-week Titration) | 0/64 (0%) | 0/64 (0%) | 51/64 (79.7%) |
| Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | 0/38 (0%) | 1/38 (2.6%) | 31/38 (81.6%) |
| Cohort 1: PF-06882961 160 mg BID (1-week Titration) | 0/63 (0%) | 1/63 (1.6%) | 56/63 (88.9%) |
| Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | 0/37 (0%) | 0/37 (0%) | 29/37 (78.4%) |
| Cohort 1: PF-06882961 200 mg BID (1-week Titration) | 0/63 (0%) | 5/63 (7.9%) | 56/63 (88.9%) |
| Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) | 0/36 (0%) | 1/36 (2.8%) | 26/36 (72.2%) |
| Cohort 3: Placebo | 0/19 (0%) | 0/19 (0%) | 13/19 (68.4%) |
| Cohort 3: PF-06882961 80mg BID (4-week Titration) | 0/37 (0%) | 2/37 (5.4%) | 28/37 (75.7%) |
| Cohort 3: PF-06882961 140mg BID (4-week Titration) | 0/37 (0%) | 2/37 (5.4%) | 33/37 (89.2%) |
| Cohort 3: PF-06882961 200mg BID (4-week Titration) | 0/36 (0%) | 3/36 (8.3%) | 34/36 (94.4%) |
| Event | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40 mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/71 | 0/62 | 0/63 | 0/64 | 0/38 | 0/63 | 0/37 | 0/63 | 1/36 | 0/19 | 0/37 | 0/37 | 0/36 |
| Bundle branch block leftCardiac disorders | 0/71 | 0/62 | 0/63 | 0/64 | 0/38 | 0/63 | 0/37 | 0/63 | 0/36 | 0/19 | 0/37 | 0/37 | 1/36 |
| NauseaGastrointestinal disorders | 0/71 | 0/62 | 0/63 | 0/64 | 0/38 | 0/63 | 0/37 | 0/63 | 0/36 | 0/19 | 0/37 | 0/37 | 1/36 |
| VomitingGastrointestinal disorders | 0/71 | 0/62 | 0/63 | 0/64 | 0/38 | 0/63 | 0/37 | 0/63 | 0/36 | 0/19 | 0/37 | 0/37 | 1/36 |
| Pharyngitis streptococcalInfections and infestations | 0/71 | 0/62 | 0/63 | 0/64 | 0/38 | 0/63 | 0/37 | 0/63 | 0/36 | 0/19 | 0/37 | 0/37 | 1/36 |
| Aortic valve stenosisCardiac disorders | 0/71 | 0/62 | 0/63 | 0/64 | 0/38 | 0/63 | 0/37 | 0/63 | 0/36 | 0/19 | 0/37 | 1/37 | 0/36 |
| Atrial fibrillationCardiac disorders | 0/71 | 0/62 | 0/63 | 0/64 | 0/38 | 0/63 | 0/37 | 0/63 | 0/36 | 0/19 | 0/37 | 1/37 | 0/36 |
| LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/71 | 0/62 | 0/63 | 0/64 | 0/38 | 0/63 | 0/37 | 0/63 | 0/36 | 0/19 | 1/37 | 0/37 | 0/36 |
| Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/71 | 0/62 | 0/63 | 0/64 | 0/38 | 0/63 | 0/37 | 0/63 | 0/36 | 0/19 | 1/37 | 0/37 | 0/36 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/71 | 0/62 | 0/63 | 0/64 | 0/38 | 0/63 | 0/37 | 0/63 | 0/36 | 0/19 | 0/37 | 1/37 | 0/36 |
| Event | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40 mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 11/71 | 28/62 | 39/63 | 41/64 | 22/38 | 36/63 | 25/37 | 34/63 | 18/36 | 2/19 | 14/37 | 27/37 | 25/36 |
| VomitingGastrointestinal disorders | 2/71 | 10/62 | 24/63 | 26/64 | 16/38 | 27/63 | 11/37 | 29/63 | 16/36 | 1/19 | 3/37 | 14/37 | 17/36 |
| DiarrhoeaGastrointestinal disorders | 7/71 | 5/62 | 17/63 | 12/64 | 9/38 | 13/63 | 3/37 | 11/63 | 6/36 | 1/19 | 8/37 | 8/37 | 9/36 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/71 | 7/62 | 8/63 | 8/64 | 10/38 | 3/63 | 4/37 | 10/63 | 6/36 | 1/19 | 2/37 | 2/37 | 8/36 |
| DyspepsiaGastrointestinal disorders | 1/71 | 6/62 | 11/63 | 5/64 | 5/38 | 13/63 | 2/37 | 13/63 | 4/36 | 1/19 | 5/37 | 3/37 | 7/36 |
| ConstipationGastrointestinal disorders | 3/71 | 8/62 | 10/63 | 7/64 | 5/38 | 12/63 | 4/37 | 9/63 | 6/36 | 2/19 | 7/37 | 2/37 | 5/36 |
| HeadacheNervous system disorders | 8/71 | 6/62 | 11/63 | 11/64 | 3/38 | 11/63 | 6/37 | 7/63 | 6/36 | 3/19 | 5/37 | 3/37 | 4/36 |
| Urinary tract infectionInfections and infestations | 3/71 | 4/62 | 8/63 | 4/64 | 1/38 | 3/63 | 0/37 | 4/63 | 2/36 | 0/19 | 4/37 | 3/37 | 5/36 |
| FatigueGeneral disorders | 5/71 | 3/62 | 4/63 | 7/64 | 0/38 | 6/63 | 5/37 | 7/63 | 2/36 | 1/19 | 5/37 | 1/37 | 1/36 |
| Abdominal distensionGastrointestinal disorders | 1/71 | 3/62 | 3/63 | 3/64 | 5/38 | 2/63 | 3/37 | 2/63 | 0/36 | 1/19 | 2/37 | 1/37 | 1/36 |
Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention.
| Age, Customized(Participants) | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40 mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18-44 years | 28 | 27 | 26 | 21 | 14 | 22 | 17 | 25 | 11 | 8 | 12 | 13 | 14 | 238 |
| 45-64 years | 34 | 31 | 30 | 36 | 17 | 34 | 20 | 31 | 20 | 9 | 24 | 24 | 19 | 329 |
| Greater than or equal to (>=)65 years | 9 | 4 | 7 | 7 | 7 | 7 | 0 | 7 | 5 | 2 | 1 | 0 | 3 | 59 |
| Sex: Female, Male(Participants) | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40 mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 45 | 40 | 41 | 42 | 22 | 41 | 22 | 41 | 23 | 12 | 23 | 23 | 22 | 397 |
| Male | 26 | 22 | 22 | 22 | 16 | 22 | 15 | 22 | 13 | 7 | 14 | 14 | 14 | 229 |
| Ethnicity (NIH/OMB)(Participants) | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40 mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 7 | 8 | 7 | 3 | 2 | 4 | 2 | 5 | 0 | 2 | 3 | 2 | 51 |
| Not Hispanic or Latino | 65 | 55 | 54 | 56 | 34 | 61 | 33 | 60 | 30 | 19 | 34 | 34 | 34 | 569 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 6 |
| Race (NIH/OMB)(Participants) | Cohorts 1 and 2: Placebo | Cohort 1: PF-06882961 40 mg BID (1-week Titration) | Cohort 1: PF-06882961 80mg BID (1-week Titration) | Cohort 1: PF-06882961 120mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) | Cohort 1: PF-06882961 160 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) | Cohort 1: PF-06882961 200 mg BID (1-week Titration) | Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) | Cohort 3: Placebo | Cohort 3: PF-06882961 80mg BID (4-week Titration) | Cohort 3: PF-06882961 140mg BID (4-week Titration) | Cohort 3: PF-06882961 200mg BID (4-week Titration) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 |
| Asian | 11 | 8 | 10 | 8 | 3 | 10 | 2 | 13 | 2 | 0 | 0 | 0 | 0 | 67 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 4 | 4 | 10 | 11 | 4 | 8 | 5 | 5 | 3 | 3 | 8 | 6 | 5 | 76 |
| White | 55 | 48 | 42 | 45 | 31 | 42 | 30 | 45 | 31 | 16 | 29 | 31 | 28 | 473 |
| More than one race | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jan 2021 to primary completion in Sep 2023, 31 months.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 31 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Danuglipron